Arcticzymes Technologies ASA
OSE:AZT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arcticzymes Technologies ASA
Other Current Liabilities
Arcticzymes Technologies ASA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Other Current Liabilities
kr12.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Other Current Liabilities
kr74.4m
|
CAGR 3-Years
79%
|
CAGR 5-Years
51%
|
CAGR 10-Years
27%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Other Current Liabilities
kr31m
|
CAGR 3-Years
38%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Other Current Liabilities
$868k
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Other Current Liabilities
kr8.4m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-3%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Other Current Liabilities
kr14.4m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
5%
|
|
Arcticzymes Technologies ASA
Glance View
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
See Also
What is Arcticzymes Technologies ASA's Other Current Liabilities?
Other Current Liabilities
12.6m
NOK
Based on the financial report for Dec 31, 2025, Arcticzymes Technologies ASA's Other Current Liabilities amounts to 12.6m NOK.
What is Arcticzymes Technologies ASA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
0%
Over the last year, the Other Current Liabilities growth was 241%. The average annual Other Current Liabilities growth rates for Arcticzymes Technologies ASA have been -5% over the past three years .
